{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T19:33:04Z","timestamp":1794252784164,"version":"4.9.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009882","name":"Regione Lombardia","doi-asserted-by":"publisher","award":["Grant 231836"],"award-info":[{"award-number":["Grant 231836"]}],"id":[{"id":"10.13039\/501100009882","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Becker muscular dystrophy (BMD) is a severe X-linked muscle disease. Age of onset, clinical variability, speed of progression and affected tissues display wide variability, making a clinical trial design for drug development very complex. The histopathological changes in skeletal muscle tissue are central to the pathogenesis, but they have not been thoroughly elucidated yet. Here we analysed muscle biopsies from a large cohort of BMD patients, focusing our attention on the histopathological muscle parameters, as fibrosis, fatty replacement, fibre cross sectional area, necrosis, regenerating fibres, splitting fibres, internalized nuclei and dystrophy evaluation. We correlated histological parameters with both demographic features and clinical functional evaluations. The most interesting results of our study are the accurate quantification of fibroadipose tissue replacement and the identification of some histopathological aspects that well correlate with clinical performances. Through correlation analysis, we divided our patients into three clusters with well-defined histological and clinical features. In conclusion, this is the first study that analyses in detail the histological characteristics of muscle biopsies in a large cohort of BMD patients, correlating them to a functional impairment. The collection of these data help to better understand the histopathological progression of the disease and can be useful to validate any pharmacological trial in which the modification of muscle biopsy is utilized as outcome measure.<\/jats:p>","DOI":"10.1186\/s40478-022-01354-3","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T12:02:58Z","timestamp":1649419378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Muscle histological changes in a large cohort of patients affected with Becker muscular dystrophy"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9293-6823","authenticated-orcid":false,"given":"Michela","family":"Ripolone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Velardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Mondello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Zanotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Magri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Minuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Cazzaniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Fortunato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Ciscato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Tiberio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Sciacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Moggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bettica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo P.","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"key":"1354_CR1","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1002\/humu.21114","volume":"30","author":"KM Flanigan","year":"2009","unstructured":"Flanigan KM, Dunn DM, von Niederhausern A, Soltanzadeh P, Gappmaier E, Howard MT et al (2009) Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat 30:1657\u20131666","journal-title":"Hum Mutat"},{"key":"1354_CR2","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3389\/fgene.2020.00131","volume":"11","author":"M Neri","year":"2020","unstructured":"Neri M, Rossi R, Trabanelli C, Mauro A, Selvatici R, Falzarano MS et al (2020) The genetic landscape of dystrophin mutations in Italy: a nationwide study. Front Genet 11:131","journal-title":"Front Genet"},{"key":"1354_CR3","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1242\/dev.069088","volume":"139","author":"F Relaix","year":"2012","unstructured":"Relaix F, Zammit PS (2012) Satellite cells are essential for skeletal muscle regeneration: the cell on the edge returns centre stage. Development 139:2845\u20132856","journal-title":"Development"},{"issue":"2","key":"1354_CR4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0960-8966(96)00422-1","volume":"7","author":"A Irintchev","year":"1997","unstructured":"Irintchev A, Zweyer M, Wernig A (1997) Impaired functional and structural recovery after muscle injury in dystrophic mdx mice. Neuromuscul Disord 7(2):117\u2013125","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"1354_CR5","doi-asserted-by":"publisher","first-page":"6264","DOI":"10.1038\/s41467-021-26516-0","volume":"12","author":"J Dort","year":"2021","unstructured":"Dort J, Orfi Z, Fabre P, Molina T, Conte TC, Greffard K et al (2021) Resolvin-D2 targets myogenic cells and improves muscle regeneration in Duchenne muscular dystrophy. Nat Commun 12(1):6264","journal-title":"Nat Commun"},{"key":"1354_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/mus.880010204","volume":"1","author":"WG Bradley","year":"1978","unstructured":"Bradley WG, Jones MZ, Mussini JM, Fawcett PR (1978) Becker-type muscular dystrophy. Muscle Nerve 1:111\u2013132","journal-title":"Muscle Nerve"},{"key":"1354_CR7","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1001\/archneur.1984.04050180051017","volume":"41","author":"R ten Houten","year":"1984","unstructured":"ten Houten R, De Visser M (1984) Histopathological findings in becker-type muscular dystrophy. Arch Neurol 41:729\u2013733","journal-title":"Arch Neurol"},{"key":"1354_CR8","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1002\/mus.880141105","volume":"14","author":"M Kaido","year":"1991","unstructured":"Kaido M, Arahata K, Hoffman EP, Nonaka I, Sugita H (1991) Muscle histology in Becker muscular dystrophy. Muscle Nerve 14:1067\u20131073","journal-title":"Muscle Nerve"},{"key":"1354_CR9","doi-asserted-by":"crossref","unstructured":"Comi GP, Niks EH, Cinnante CM, Kan HE, Vandenborne K, Willcocks RJ, et al (2021) Characterization of patients with Becker muscular dystrophy by histology, magnetic resonance imaging, function, and strength assessments. Muscle Nerve","DOI":"10.1002\/mus.27475"},{"issue":"4","key":"1354_CR10","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1007\/s13311-018-00687-z","volume":"15","author":"PB Shieh","year":"2018","unstructured":"Shieh PB (2018) Emerging strategies in the treatment of duchenne muscular dystrophy. Neurotherapeutics 15(4):840\u2013848","journal-title":"Neurotherapeutics"},{"key":"1354_CR11","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","volume":"26","author":"P Bettica","year":"2016","unstructured":"Bettica P, Petrini S, D\u2019Oria V, D\u2019Amico A, Catteruccia M, Pane M et al (2016) Histological effects of givinostat in boys with Duchenne muscular dystrophy. Neuromuscul Disord 26:643\u2013649","journal-title":"Neuromuscul Disord"},{"key":"1354_CR12","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1212\/WNL.0000000000002147","volume":"85","author":"L Peverelli","year":"2015","unstructured":"Peverelli L, Testolin S, Villa L, D\u2019Amico A, Petrini S, Favero C et al (2015) Histologic muscular history in steroid-treated and untreated patients with Duchenne dystrophy. Neurology 85:1886\u20131893","journal-title":"Neurology"},{"key":"1354_CR13","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/nan.12414","volume":"44","author":"M Ripolone","year":"2018","unstructured":"Ripolone M, Violano R, Ronchi D, Mondello S, Nascimbeni A, Colombo I et al (2018) Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD). Neuropathol Appl Neurobiol 44:449\u2013462","journal-title":"Neuropathol Appl Neurobiol"},{"key":"1354_CR14","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","volume":"77","author":"JR Mendell","year":"2020","unstructured":"Mendell JR, Sahenk Z, Lehman K, Nease C, Lowes LP, Miller NF et al (2020) Assessment of Systemic Delivery or AAVrh74.MHCK7.micro-dystrophin in children with duchenne muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol 77:1122\u20131131","journal-title":"JAMA Neurol"},{"key":"1354_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2147\/JPR.S82970","volume":"8","author":"E Backryd","year":"2015","unstructured":"Backryd E, Ghafouri B, Carlsson AK, Olausson P, Gerdle B (2015) Multivariate proteomic analysis of the cerebrospinal fluid of patients with peripheral neuropathic pain and healthy controls-a hypothesis-generating pilot study. J Pain Res 8:321\u2013333","journal-title":"J Pain Res"},{"key":"1354_CR16","doi-asserted-by":"publisher","first-page":"11894","DOI":"10.1038\/srep11894","volume":"5","author":"P Olausson","year":"2015","unstructured":"Olausson P, Gerdle B, Ghafouri N, Sjostrom D, Blixt E, Ghafouri B (2015) Protein alterations in women with chronic widespread pain-An explorative proteomic study of the trapezius muscle. Sci Rep 5:11894","journal-title":"Sci Rep"},{"key":"1354_CR17","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1039\/c3mb70194h","volume":"9","author":"AM Wheelock","year":"2013","unstructured":"Wheelock AM, Wheelock CE (2013) Trials and tribulations of \u2019omics data analysis: assessing quality of SIMCA-based multivariate models using examples from pulmonary medicine. Mol Biosyst 9:2589\u20132596","journal-title":"Mol Biosyst"},{"key":"1354_CR18","unstructured":"Eriksson L, Byrne T, Johansson E, Trygg J, Vikstrom C (2013) Multi- and megavariate data analysis: basic principles and applications, 3rd edn. MKS Umetrics AB, Malmo"},{"key":"1354_CR19","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1093\/brain\/awr291","volume":"134","author":"K Anthony","year":"2011","unstructured":"Anthony K, Cirak S, Torelli S, Tasca G, Feng L, Arechavala-Gomeza V et al (2011) Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain 134:3547\u20133559","journal-title":"Brain"},{"key":"1354_CR20","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/ana.25951","volume":"89","author":"Y de Feraudy","year":"2021","unstructured":"de Feraudy Y, Ben-Yaou R, Wahbi K, Stalens C, Stantzou A, Laugel V, Desguerre I, FILNEMUS Network, Servais L, Leturcq F, Amthor H (2021) Very low residual dystrophin quantity is associated with milder dystrophinopathy. Ann Neurol 89:280\u2013292","journal-title":"Ann Neurol"},{"key":"1354_CR21","first-page":"179","volume":"39","author":"EP Hoffman","year":"2020","unstructured":"Hoffman EP (2020) Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies. Acta Myol 39:179\u2013186","journal-title":"Acta Myol"},{"key":"1354_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.semcdb.2016.09.013","volume":"64","author":"AL Serrano","year":"2017","unstructured":"Serrano AL, Mu\u00f1oz-C\u00e1noves P (2017) Fibrosis development in early-onset muscular dystrophies: Mechanisms and translational implications. Semin Cell Dev Biol 64:181\u2013190","journal-title":"Semin Cell Dev Biol"},{"issue":"5","key":"1354_CR23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/WCO.0b013e32834aa3f1","volume":"24","author":"TA Partridge","year":"2011","unstructured":"Partridge TA (2011) Impending therapies for Duchenne muscular dystrophy. Curr Opin Neurol 24(5):415\u2013422","journal-title":"Curr Opin Neurol"},{"key":"1354_CR24","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.addr.2018.02.009","volume":"129","author":"S Bersini","year":"2018","unstructured":"Bersini S, Gilardi M, Mora M, Krol S, Arrigoni C, Candrian C et al (2018) Tackling muscle fibrosis: from molecular mechanisms to next generation engineered models to predict drug delivery. Adv Drug Deliv Rev 129:64\u201377","journal-title":"Adv Drug Deliv Rev"},{"key":"1354_CR25","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.2147\/NDT.S93873","volume":"12","author":"JK Mah","year":"2016","unstructured":"Mah JK (2016) Current and emerging treatment strategies for Duchenne muscular dystrophy. Neuropsychiatr Dis Treat 12:1795\u20131807","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1354_CR26","first-page":"172","volume":"38","author":"C Angelini","year":"2019","unstructured":"Angelini C, Marozzo R, Pegoraro V (2019) Current and emerging therapies in Becker muscular dystrophy (BMD). Acta Myol 38:172\u2013179","journal-title":"Acta Myol"},{"key":"1354_CR27","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.pmr.2012.06.006","volume":"23","author":"NC Joyce","year":"2012","unstructured":"Joyce NC, Oskarsson B, Jin LW (2012) Muscle biopsy evaluation in neuromuscular disorders. Phys Med Rehabil Clin N Am 23:609\u2013631","journal-title":"Phys Med Rehabil Clin N Am"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-022-01354-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40478-022-01354-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-022-01354-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T12:24:15Z","timestamp":1649420655000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-022-01354-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1354"],"URL":"https:\/\/doi.org\/10.1186\/s40478-022-01354-3","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,8]]},"assertion":[{"value":"24 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MR, DV, SM, SZ, FM, EM, FF, PC, FT, MS, MM\u2014Disclosures: None. SC is employee of Italfarmaco SpA, sponsor of the clinical study. PB is employee of Italfarmaco SpA, sponsor of the clinical study. GPC participated to Advisory boards of Italfarmaco SpA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}